The association of brain-derived neurotrophic factor with the diagnosis and treatment response in depression

Introduction: Recent evidence from the studies evaluating the association between brain-derived neurotrophic factor (BDNF) concentration/levels, BDNF Val66Met (rs6265) polymorphism, and major depressive disorders, referred as depression, and the association between BDNF levels and/or BDNF Val66Met with the treatment response in depression is presented.Areas covered: This mini review focuses on the changes in the peripheral BDNF levels in blood (serum, plasma, platelets) in patients with depression before or after treatment with antidepressant drugs or different therapeutic strategies. In addition, this review describes the recent data on the possible association between different antidepressants/therapeutic strategies and the particular BDNF Val66Met genotypes, evaluating the risk alleles associated with the response in patients with depression.Expert opinion: BDNF has an important role in the pathophysiology and treatment response in depression. Most data reveal that peripheral BDNF levels are lower before than after antidepressant treatment and might be used as potential biomarkers of therapeutic response. Novel therapeutic strategies should target restoring/increasing BDNF levels.

Automated summary

This mini review presents recent evidence on the association between brain-derived neurotrophic factor (BDNF) concentration/levels, BDNF Val66Met (rs6265) polymorphism, and major depressive disorders. It focuses on the changes in peripheral BDNF levels before and after treatment with antidepressant drugs or different therapeutic strategies, as well as the association between different antidepressants/therapeutic strategies and BDNF Val66Met genotypes. The expert opinion suggests that BDNF plays an important role in the pathophysiology and treatment response in depression, and peripheral BDNF levels may serve as potential biomarkers of therapeutic response.